The
clinical
presentation
,
treatment
,
response
patient
EBVMCU
base
tongue
presented
.

Interim
follow-up
patient
revealed
complete
remission
discontinuation
immunosuppression
rituximab
therapy
.

A
review
literature
supports
conservative
management
reduction
immunosuppression
.

Overall
,
96.6
%
patients
follow-up
greater
2
months
achieved
complete
remission
conservative
management
.

The
current
study
largest
series
report
clinical
presentation
treatment
outcomes
EBVMCU
head
neck
.

